Moderna to Present at Upcoming Investor Conferences in March
March 04 2019 - 5:30PM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced its participation in the following
upcoming investor conferences:
- Cowen and Company 39th
Annual Health Care Conference in Boston on Monday, March 11,
2019 at 2:50 p.m. ET.
- Barclays Global Healthcare
Conference 2019 in Miami on Thursday, March 14, 2019 at 8:30
a.m. ET.
- Oppenheimer 29th
Annual Healthcare Conference in New York on Tuesday, March
19, 2019 at 8:35 a.m. ET.
A live webcast of each presentation will be available under
“Events & Presentations” in the Investors section of the
Moderna website at https://investors.modernatx.com/. A replay of
each webcast will be archived on Moderna’s website for 30 days
following the presentations.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create
a new class of transformative medicines for patients. mRNA
medicines are designed to direct the body’s cells to produce
intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases
and cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge,
Mass., Moderna currently has strategic alliances for
development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of
Defense and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office
of the Assistant Secretary for Preparedness and
Response (ASPR) within the U.S. Department of Health and
Human Services (HHS). Moderna has been ranked in the
top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more,
visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190304006007/en/
Moderna Contacts:Investors:Lorence KimChief
Financial
Officer617-209-5849Lorence.kim@modernatx.comMedia:Jason
GlashowHead, Corporate
Communications617-674-5648Jason.glashow@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024